Do not use for diagnosis of Epstein-Barr virus infectious mononucleosis. May aid in the detection and prognosis of nasopharyngeal carcinoma.
Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Chemiluminescent Immunoassay
New York DOH Approval Status
Serum Separator Tube (SST).
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens.
Contaminated, heat-inactivated, or grossly hemolyzed specimens.
Label specimens plainly as acute or convalescent.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (Avoid repeated freeze/thaw cycles).
|0050235||Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgG||Effective February 19, 2013
17.9 U/mL or less: Not Detected
18.0-21.9 U/mL: Indeterminate. Repeat testing in 10-14 days may be helpful.
22.0 U/mL or greater: Detected
|0051626||Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgA||Effective February 16, 2021
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0050235||EBV Antibody to Viral Capsid Antigen IgG||7885-7|
|0051626||EBV Antibody To Viral Capsid Antigen IgA||31369-2|
- EBV and VCA Ab
- EBV Antibodies
- EBV VCA- Ab
- Infectious Mononucleosis